Effectiveness of EPA+DHA from yellow stripe scad fish on lipid profile, platelet and endothelial-related activation biomarkers among overweight adults

Overweight is a global health condition that can lead to cardiovascular diseases (CVDs). Eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) from salmon have beneficial effects on CVDs, while local yellow stripe scad (YSS), has been described as having same. However, the beneficial effects of...

Full description

Saved in:

Bibliographic Details
Main Author:	Abdulrahman, Yakubu
Format:	Thesis
Language:	English
Published:	2020
Subjects:	Obesity Eicosanoids - Therapeutic use Docosahexaenoic Acids - Therapeutic use
Online Access:	http://psasir.upm.edu.my/id/eprint/97985/1/FPSK%20%28p%29%202021%2034%20IR.pdf
Tags:	Add Tag No Tags, Be the first to tag this record!

id	my-upm-ir.97985
record_format	uketd_dc
institution	Universiti Putra Malaysia
collection	PSAS Institutional Repository
language	English
advisor	Md Noor, Sabariah
topic	Obesity Eicosanoids - Therapeutic use Docosahexaenoic Acids - Therapeutic use
spellingShingle	Obesity Eicosanoids - Therapeutic use Docosahexaenoic Acids - Therapeutic use Abdulrahman, Yakubu Effectiveness of EPA+DHA from yellow stripe scad fish on lipid profile, platelet and endothelial-related activation biomarkers among overweight adults
description	Overweight is a global health condition that can lead to cardiovascular diseases (CVDs). Eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) from salmon have beneficial effects on CVDs, while local yellow stripe scad (YSS), has been described as having same. However, the beneficial effects of EPA+DHA still remain ambiguous. The present study investigated the impact of 900mg EPA+DHA intake from YSS and salmon on parameters including body mass index (BMI), serum leptin, lipid profile and blood pressure (atherosclerosis marker), platelet activation markers (thrombotic makers), platelet and endothelial inflammation markers as (CVD markers) and protein expression level of NF-kB and PPAR-γ (as therapeutic markers) on healthy overweight subjects. For 60 days, equally randomized subjects received either 269g of YSS whole fish per day, to obtain 2,103mg of EPA+DHA per day for three days in a week that provides 6,310 mg of EPA+DHA (approximately 900mg/day) or 217g of salmon fish fillet per day that provides 2,103mg of EPA+DHA per day for three days and contained 6,310 mg of EPA+DHA/week (approximately 900mg/day).The primary and secondary results were recorded and data were analyzed quantitatively and qualitatively by a twotailed paired Student's T-test and Analysis of Covariance (ANCOVA) respectively. Significant differences were observed in serum leptin for both YSS (+2.0 ng/ml) and salmon (+1.9 ng/ml). Increased significant differences were observed in HDLC (+0.0711mmol/L) and LDL-C (+0.171mmol/L) in YSS-baseline but not in VLDL-cholesterol (+0.02mmol/L). Significant differences were also observed in VLDL (+0.049 mmol/L) and HDL-C (+0.06 mmol/L) in salmon-baseline but not in LDL-C. Non-significant differences were also observed in body mass index (BMI) (+0.05kg/m2), leptin (+0.541ng/ml), HDL-C (+0.008mmol/L), LDL-C (+0.015mmol/L), and VLDL-C (+0.03mmol/L) in YSS and salmon, as independent variables including the effects of time and interactions. No significant difference (p>0.05) was observed for PMP-CD62 (+222.6 PMPs/μl), PMP-CD41 (316.3 PMPs/μl), and PMP-PS-Annexin-5 (237.5 PMPs/μl) as independent variables for YSS and salmon including the effects of time and interactions. No significant difference was also observed in vWF (+11.2pg/ml), MCP-I (+0.5pg/ml), P-selectin (+20.5pg/ml), sCD40L (+0.3pg/ml), IL-1β (+0.378pg/ml) and TNF-α (+1.3pg/ml) including the effects of time and interactions in YSS and salmon as independent variables. The study observed no significant difference in NF-kB, (3.9 ng/ml) in YSS-salmon and PPAR-γ (+3.7ng/ml) in YSS-salmon as independent variable. The inferential statistic, “ANCOVA" showed that YSS and salmon treatments as an independent variable was not significant in BMI, serum leptin, lipid profile, blood pressure as (atherosclerotic makers) and platelet activation markers as (thrombotic makers), platelet and endothelial inflammation markers as (CVD markers) and protein expression level of NF-kB and PPAR-γ as (therapeutic markers). Qualitative data analysis showed that both primary and secondary data, were similar in performance. The study shows positive effects of EPA+DHA treatments from salmon and from YSS. The study upheld the (Ho) null hypothesis in which the effect of EPA+DHA from salmon on atherosclerosis, thrombosis, and CVD related parameters did not change and was no different from EPA+DHA in YSS including the effects of time and interactions. In future intervention investigations on EPA+DHA, cellular phospholipid membrane content, a controlled randomized study, is vital to further validate the similarity effects of EPA+DHA from both YSS and salmon intake.
format	Thesis
qualification_level	Doctorate
author	Abdulrahman, Yakubu
author_facet	Abdulrahman, Yakubu
author_sort	Abdulrahman, Yakubu
title	Effectiveness of EPA+DHA from yellow stripe scad fish on lipid profile, platelet and endothelial-related activation biomarkers among overweight adults
title_short	Effectiveness of EPA+DHA from yellow stripe scad fish on lipid profile, platelet and endothelial-related activation biomarkers among overweight adults
title_full	Effectiveness of EPA+DHA from yellow stripe scad fish on lipid profile, platelet and endothelial-related activation biomarkers among overweight adults
title_fullStr	Effectiveness of EPA+DHA from yellow stripe scad fish on lipid profile, platelet and endothelial-related activation biomarkers among overweight adults
title_full_unstemmed	Effectiveness of EPA+DHA from yellow stripe scad fish on lipid profile, platelet and endothelial-related activation biomarkers among overweight adults
title_sort	effectiveness of epa+dha from yellow stripe scad fish on lipid profile, platelet and endothelial-related activation biomarkers among overweight adults
granting_institution	Universiti Putra Malaysia
publishDate	2020
url	http://psasir.upm.edu.my/id/eprint/97985/1/FPSK%20%28p%29%202021%2034%20IR.pdf
_version_	1747813825867939840
spelling	my-upm-ir.979852022-07-13T08:10:44Z Effectiveness of EPA+DHA from yellow stripe scad fish on lipid profile, platelet and endothelial-related activation biomarkers among overweight adults 2020-11 Abdulrahman, Yakubu Overweight is a global health condition that can lead to cardiovascular diseases (CVDs). Eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) from salmon have beneficial effects on CVDs, while local yellow stripe scad (YSS), has been described as having same. However, the beneficial effects of EPA+DHA still remain ambiguous. The present study investigated the impact of 900mg EPA+DHA intake from YSS and salmon on parameters including body mass index (BMI), serum leptin, lipid profile and blood pressure (atherosclerosis marker), platelet activation markers (thrombotic makers), platelet and endothelial inflammation markers as (CVD markers) and protein expression level of NF-kB and PPAR-γ (as therapeutic markers) on healthy overweight subjects. For 60 days, equally randomized subjects received either 269g of YSS whole fish per day, to obtain 2,103mg of EPA+DHA per day for three days in a week that provides 6,310 mg of EPA+DHA (approximately 900mg/day) or 217g of salmon fish fillet per day that provides 2,103mg of EPA+DHA per day for three days and contained 6,310 mg of EPA+DHA/week (approximately 900mg/day).The primary and secondary results were recorded and data were analyzed quantitatively and qualitatively by a twotailed paired Student's T-test and Analysis of Covariance (ANCOVA) respectively. Significant differences were observed in serum leptin for both YSS (+2.0 ng/ml) and salmon (+1.9 ng/ml). Increased significant differences were observed in HDLC (+0.0711mmol/L) and LDL-C (+0.171mmol/L) in YSS-baseline but not in VLDL-cholesterol (+0.02mmol/L). Significant differences were also observed in VLDL (+0.049 mmol/L) and HDL-C (+0.06 mmol/L) in salmon-baseline but not in LDL-C. Non-significant differences were also observed in body mass index (BMI) (+0.05kg/m2), leptin (+0.541ng/ml), HDL-C (+0.008mmol/L), LDL-C (+0.015mmol/L), and VLDL-C (+0.03mmol/L) in YSS and salmon, as independent variables including the effects of time and interactions. No significant difference (p>0.05) was observed for PMP-CD62 (+222.6 PMPs/μl), PMP-CD41 (316.3 PMPs/μl), and PMP-PS-Annexin-5 (237.5 PMPs/μl) as independent variables for YSS and salmon including the effects of time and interactions. No significant difference was also observed in vWF (+11.2pg/ml), MCP-I (+0.5pg/ml), P-selectin (+20.5pg/ml), sCD40L (+0.3pg/ml), IL-1β (+0.378pg/ml) and TNF-α (+1.3pg/ml) including the effects of time and interactions in YSS and salmon as independent variables. The study observed no significant difference in NF-kB, (3.9 ng/ml) in YSS-salmon and PPAR-γ (+3.7ng/ml) in YSS-salmon as independent variable. The inferential statistic, “ANCOVA" showed that YSS and salmon treatments as an independent variable was not significant in BMI, serum leptin, lipid profile, blood pressure as (atherosclerotic makers) and platelet activation markers as (thrombotic makers), platelet and endothelial inflammation markers as (CVD markers) and protein expression level of NF-kB and PPAR-γ as (therapeutic markers). Qualitative data analysis showed that both primary and secondary data, were similar in performance. The study shows positive effects of EPA+DHA treatments from salmon and from YSS. The study upheld the (Ho) null hypothesis in which the effect of EPA+DHA from salmon on atherosclerosis, thrombosis, and CVD related parameters did not change and was no different from EPA+DHA in YSS including the effects of time and interactions. In future intervention investigations on EPA+DHA, cellular phospholipid membrane content, a controlled randomized study, is vital to further validate the similarity effects of EPA+DHA from both YSS and salmon intake. Obesity Eicosanoids - Therapeutic use Docosahexaenoic Acids - Therapeutic use 2020-11 Thesis http://psasir.upm.edu.my/id/eprint/97985/ http://psasir.upm.edu.my/id/eprint/97985/1/FPSK%20%28p%29%202021%2034%20IR.pdf text en public doctoral Universiti Putra Malaysia Obesity Eicosanoids - Therapeutic use Docosahexaenoic Acids - Therapeutic use Md Noor, Sabariah

Effectiveness of EPA+DHA from yellow stripe scad fish on lipid profile, platelet and endothelial-related activation biomarkers among overweight adults

Similar Items